Efficacy And Safety Of ARNI In Treating Refractory Hypertension Caused By Tyrosine Kinase Inhibitors

Objective:To explore the efficacy and safety of sacubaprotrovalsartan sodium(ARNI)angiotensin receptor-enkephalin enzyme inhibition in the treatment of resistant hypertension caused by tyrosine kinase inhibitors,and to provide a basis for doctors to choose more effective and safe treatment options.Methods:A total of 62 tumor patients with refractory hypertension caused by tyrosine kinase inhibitors from April 2020 to September 2022 were selected as the study subjects,who were divided into observation group and control group according to the random number table method,with 31 cases in each group.The control group received oral treatment with losartan potassium tablets,the observation group patients received oral treatment with sarkubactrosovalsartan sodium tablets,and both groups were treated for 8 weeks.To compare the clinical treatment effect of the two groups,the mean values of blood pressure before,2 weeks,4 weeks and 8 weeks of renal function [creatinine(Scr),urea nitrogen(BUN),cystatin(Cys)-C],electrolytes,potassium(K +),blood calcium(Ca +),blood sodium(Na +)],and drug adverse reactions(dizziness,vomiting,nausea,tachycardia,and drowsiness)between the two groups.Results:The total response rate in the observation group was 96.77%(30 / 31)and 77.42%(24 / 31)in the control group,which was significantly higher than patients in the control group(P<0.05).Dynamic systolic BP and dynamic diastolic BP showed a trend over time and varied according to different groups.At 2,4 and 8 weeks of treatment,both dynamic SBP and DBP were decreased,but the observed group was statistically significant(all P <0.05).After treatment,Scr,BUN,and Cys-C levels were decreased in both groups,and the observation group was lower than the control group(P <0.05).After treatment,K +,Ca +,and Na + levels did not change significantly in both groups,and there was no significant difference between the groups(P> 0.05).The total incidence of dizziness,vomiting,malignancy,tachycardia,and drowsiness was compared between the two groups(P> 0.05).Conclusion:ARNI can improve the treatment effect of tyrosine kinase inhibitors in causing resistant hypertension,reduce ambulatory blood pressure,improve renal function,maintain electrolyte balance,and do not increase adverse drug reactions.